PRODUCTS IN TOPICAL APPLICATIONS
Topical Applications
In topical applications phospholipids can promote drug-skin interaction, strengthen the skin barrier, act as moisturizer and increase the residence time of the drug substance at the skin surface.
Biocompatibility, regulatory status, and performance make phospholipids a preferred type of excipient. Phospholipids in O/W emulsions promote solubilization of poorly water-soluble compounds, which can be incorporated into creams. Liposomes are suitable for encapsulation of hydrophilic as well as lipophilic drug substances and are utilized in dosage forms such as gels, creams, and liquid sprays.
Phospholipids are excellent excipients for topical administration. Due to their non-toxic and non-irritating properties as well as their natural and renewable origin, they are well suited to meet the high-quality demands for state-of-the-art dermal products. In addition to their excellent excipient properties, they can also help to improve the dermal structure of irritated or damaged skin. They are suitable for replacing missing or attenuated substances in the stressed skin (e.g., linoleic acid) via intrinsic metabolism pathways.
Formulations with unsaturated phospholipids tend to penetrate deeper into the skin compared to formulations without phospholipids, thereby assisting delivery of the drug to its target.
Hydrogenated (saturated) phospholipids increase retention times on the surface of the skin and help to keep the barrier function intact.
Emulsions
Phospholipids serve as emulsifiers for O/W and W/O emulsions in cream-type formulations. Poorly water-soluble actives may be dissolved in the oily components of the formulations.
Liposomes
Phospholipids in the form of liposomes enhance the pharmaceutical profile of topical formulations. Based on either unsaturated or hydrogenated phospholipids, these liposomes may be further processed in diverse topical formulations, e.g. gel products.
Lamellar Systems
The lamellar arrangement of lipids effectively supports the recovery of the skin barrier. Our SLM Skin Lipid Matrix® is a base formulation of multi-lamellar structured hydrogenated phospholipids that can be easily formulated into topical products. The lamellar layers aim to restore the protective layer of the skin barrier and can help to retain APIs at the site of action.
Sprays
For topical sprays direct dissolution of APIs is achieved with phospholipids in a solvent. This application form provides an easy and effective way of dermal drug delivery.
The products shown below represent a selection of our extensive product range.
Products
Soybean | ||
LIPOID S 45 | Lecithin fraction with 45 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID S 75 | Phospholipids with 70 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID S 100 | Phosphatidylcholine, content ≥ 94.0 % | CAS-No. 97281-47-5 |
PHOSPHOLIPON® 90 G | Phosphatidylcholine, content ≥ 94.0 %, granulated | CAS-No. 97281-47-5 |
PHOSPHOLIPON® 80 H | Phospholipids, hydrogenated, with 70 % phosphatidylcholine | CAS-No. 92128-87-5 |
PHOSPHOLIPON® 90 H | Phosphatidylcholine, hydrogenated, content ≥ 90.0 % | CAS-No. 97281-48-6 |
PHOSAL® MCT | 30 % LIPOID S 75 (USP-NF) in medium-chain trigylcerides (USP-NF) | |
PHOSAL® 50 PG | Phosphatidylcholine in propylene glycol, content ≥ 50.0 % | |
PHOSAL® 50 SA+ | Phospholipid formulation of phosphatidylcholine, content ≥ 50.0 % in safflower seed oil | |
PHOSAL® 53 MCT | Phosphatidylcholine in medium-chain triglyceride, content ≥ 53.0 % | |
PHOSAL® 75 SA | Phosphatidylcholine in ethanol and safflower oil, content ≥ 72.0 % | |
SLM Skin Lipid Matrix® 2026 | Base formulation with hydrogenated phosphatidylcholine and skin identical lipids of the stratum corneum | |
Non-GMO Soybean | ||
LIPOID P 45 | Lecithin fraction with 45 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID P 75 | Phospholipids with 70 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID P 100 | Phosphatidylcholine, content ≥ 90.0 % | CAS-No. 97281-47-5 |
LIPOID P LPC 80 | Lysophosphatidylcholine, content 80 % and ≤ 20 % phosphatidylcholine | CAS-No. 9008-30-4 |
LIPOID P 75-3 | Phospholipids, hydrogenated, with 70 % phosphatidylcholine | CAS-No. 92128-87-5 |
LIPOID P 100-3 | Phosphatidylcholine, hydrogenated, content ≥ 90.0 % | CAS-No. 97281-48-6 |
LIPOID Liposome® Basic | Pre-formulated liposomes with 15 % phospholipids in glycerol | |
LIPOID Liposome® 0041 | Aqueous liposome dispersion with soybean phospholipids | |
Sunflower (Non-GMO) | ||
LIPOID H 90 | Phosphatidylcholine, content ≥ 90.0 % | CAS-No. 97281-49-7 |
LIPOID H 100 | Phosphatidylcholine, content ≥ 94.0 % | CAS-No. 97281-49-7 |
LIPOID H 100-3 | Phosphatidylcholine from sunflower, hydrogenated, content ≥ 90.0 % | CAS-No. 92128-87-5 |
PHOSAL® H 50 | Phosphatidylcholine in sunflower oil, content ≥ 50.0 % | |
SLM Eco® | Base formulation with hydrogenated phosphatidylcholine (non-GMO) and skin identical lipids of the stratum corneum | |
Purified Fatty Acids and Fatty Acid Salts | ||
LIPOID Purified Oleic Acid | Oleic acid of vegetable origin (Ph.Eur.), content ≥ 65.0 % | CAS-No. 112-80-1 |
- Pharmaceutical Applications
- Parenteral Applications
- Oral Applications
- Topical Applications
- Pulmonary Applications
- Ocular Applications
- Active Pharmaceutical Ingredients